P-125

Quick links

Choose a section

Quick links to important sections

Advertisements

P-125

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of P-125

Property Description
Active Ingredient Acetaminophen (Paracetamol)
Pharmacological Class Analgesic and Antipyretic
Form Tablet, Solution, Suspension, Suppository
Common Use Symptomatic relief of pain and fever
Origin Synthetic chemical compound

P-125 is a pharmaceutical product containing a single active chemical substance known internationally as Acetaminophen, which is chemically synonymous with Paracetamol (N-acetyl-para-aminophenol, or APAP). This medication is a synthetic compound derived from the para-aminophenol class. The pharmacological classification confirms its dual function as both a Non-opioid Analgesic (a substance to relieve pain) and an Antipyretic (a substance to reduce fever), defining its primary role in symptomatic management.

Its role as an essential medicine for general pain and fever control is recognized for its utility in public health and general symptomatic relief. Acetaminophen is designated as an Antipyretic and Analgesic for its effectiveness in reducing elevated body temperature and discomfort.

P-125 is made available in a variety of dosage forms to facilitate different routes of administration. Preparations include oral forms such as tablets and oral suspensions, alongside forms designed for non-oral delivery, such as suppositories and sterile solutions for intravenous infusion. The final composition consists of the active ingredient combined with necessary pharmaceutical excipients or an aqueous vehicle appropriate for the final presentation, ensuring flexibility for both adult and pediatric patient groups.

Regulatory References

  1. World Health Organization (WHO)
Advertisements

What side effects are possible with P-125?

Possible Side Effects and Safety Information

The safety profile of P-125 (Acetaminophen/Paracetamol) is documented in official regulatory sources, with adverse reactions categorized by frequency and the body system affected. The most critical safety consideration established by all major government authorities is the risk of dose-dependent hepatotoxicity, meaning the potential for severe, life-threatening liver damage is directly tied to the total amount administered.

Officially Documented Adverse Reactions

Adverse effects are formally grouped into affected System-Organ Classes (SOCs), which include Hepatobiliary Disorders, Immune System Disorders, Blood and Lymphatic System Disorders, and Skin and Subcutaneous Tissue Disorders.

Classification Examples of Reactions
Rare (1-10 in 10,000) Specific blood disorders, non-severe hypersensitivity reactions
Very Rare (<1 in 10,000) Serious Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson syndrome (SJS)

Critical Safety Considerations

Serious Adverse Reactions highlighted in regulatory warnings include Acute Liver Failure (associated with dose excess), SCARs, and severe systemic reactions like Anaphylactic Shock.

The safety profile enforces several constraints:

  • Dose Constraint: All regulatory bodies mandate a strict maximum daily dose to mitigate the risk of dose-dependent liver toxicity.
  • Concomitant Use: There is a universal caution against using P-125 simultaneously with any other medication containing Acetaminophen/Paracetamol.
  • Population Notes: Safety restrictions apply to individuals with severe hepatic impairment and caution is advised for those with severe renal impairment.

This structure ensures that the primary risks—particularly the potential for liver damage tied to dose—are clearly communicated in a non-instructional, safety-focused framework.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

This information describes the documented profile of P-125 overdose, based strictly on official government regulatory documents (such as FDA Prescribing Information and EMA SmPC).

Documented Manifestations and Risks

Official labeling indicates that P-125 overexposure may initially present with nausea, vomiting, dizziness, and tachycardia. Severe, potentially life-threatening outcomes documented include respiratory depression, seizures, and cardiac arrest. The onset of severe symptoms may be delayed, sometimes occurring several hours after ingestion.

Documented Manifestations (Examples) Serious Outcomes (Regulatory Listing)
Vomiting, Dizziness, Altered Mental Status Seizures, Respiratory Depression, Cardiac Arrest

Emergency Actions Mandated by Regulation

Regulatory agencies explicitly require that immediate medical attention must be sought for any suspected overdose of P-125, even if the individual currently appears well or symptoms have not yet developed.

Specific instructions documented for healthcare providers include the use of gastric decontamination procedures and the administration of a pharmacological antidote under certain documented conditions. Continuous observation and monitoring of specific physiological systems (e.g., cardiac and respiratory function) are required components of management.

Population-Specific Considerations

Official documents note that individuals with underlying hepatic impairment are identified as a population with increased susceptibility to severe and potentially fatal outcomes following an overdose.

Advertisements

Therapeutic Uses of P-125

Symptomatic Management: What P-125 Treats

P-125 is commonly used for symptomatic management, generally applied in contexts where temporary support for heightened symptoms is needed. It is considered relevant when supportive symptom management is appropriate across both pain and fever domains. The medication is generally applied to help address symptoms related to physical discomfort and systemic imbalance.

It is commonly used across conditions presenting with acute episodes or fluctuating symptom patterns, including those associated with headache, muscular aches, dental pain, menstrual cramps, and the discomfort of the common cold or flu.

“The antipyretic function may provide support that helps ease the overall symptom burden during periods of heightened symptoms.”

Key Therapeutic Benefits

P-125 is relevant in contexts involving heightened systemic burden caused by fever, where its antipyretic function may assist with reducing elevated body temperature. In addition, its analgesic role assists with easing mild to moderate pain, providing support that helps improve day-to-day comfort during symptomatic periods. It is often used during phases when symptoms become more noticeable, offering supportive relief when symptoms interfere with routine activities.


Quick Fact: Relief for Mild to Moderate Pain and Fever

Advertisements

Eligibility and Restrictions for Use

P-125 (Acetaminophen/Paracetamol) is widely approved for use across the lifespan, but official regulatory documents establish strict contraindications and use restrictions based on a patient’s health status.

Absolute Contraindications

Use is contraindicated (prohibited) for specific high-risk populations, as defined in official labeling:

  • Severe Hepatic Impairment: Patients with severe active liver disease or severe hepatic impairment must not use this medicine due to the high risk of severe hepatotoxicity.
  • Hypersensitivity: Individuals with a documented history of severe allergic reaction to the active substance or any excipients are prohibited from use.

Conditional Use and Restrictions

Population Group Regulatory Status
Mild-to-Moderate Hepatic Impairment Caution is advised, and use may be restricted. Risk is elevated for patients with chronic alcoholism or severe malnutrition (glutathione depletion states).
Severe Renal Impairment Caution is required. The dosing interval may need to be extended as specified in the labeling.
Pregnancy May be used when clinically needed, at the lowest effective dose for the shortest duration.
Pediatric Eligibility Approved for all ages, but minimum age/weight thresholds apply to specific formulations (e.g., infants under 12 weeks of age for some forms).

The official eligibility profile is structured around the integrity of organ function and immunological response, defining clear boundaries between permitted, restricted, and prohibited populations.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Interaction patterns involving P-125 (Acetaminophen/Paracetamol) are classified based on regulatory documentation from government agencies, focusing strictly on changes in exposure, pharmacodynamic outcomes, or required administration restrictions.

Combinations and Restrictions

Category Documented Constraint
Prohibited Combination Co-administration with other Acetaminophen-containing products is strictly prohibited to prevent the risk of accidental overdose leading to severe hepatic injury.
Timing Rule Cholestyramine reduces P-125 absorption, necessitating that its administration be separated from P-125 by at least one hour to mitigate this effect.

Pharmacodynamic and Metabolic Interaction Patterns

Long-term, regular daily use of P-125 is documented to enhance the anticoagulant effect of Warfarin and other Coumarins, which may increase the risk of bleeding. The interaction is noted to be dose-dependent.

Interactions involving metabolic alteration occur with substances classified as hepatic enzyme inducers, such as Rifampicin and certain antiepileptic drugs (e.g., Phenytoin, Carbamazepine). This co-administration may increase the formation of toxic metabolites, thereby raising the potential for liver damage.

Substances that affect P-125's clearance, like Probenecid, reduce its clearance by approximately 50%, a factor that may require adjustment in the P-125 amount administered.

Interactions with Substances

Regular consumption of three or more alcoholic drinks daily is documented to increase the risk of severe liver damage when combined with P-125. The herbal product St. John's Wort is also listed as an enzyme-inducer that can result in reduced P-125 concentrations and effectiveness.

Advertisements

Mechanism of Action

P-125 functions as a selective allosteric antagonist at the G-protein coupled receptor X ( GPCR-X), which is prominently expressed in the smooth muscle cells of the systemic vasculature and in specific central nervous system nuclei.

Its selectivity is derived from high-affinity binding to an allosteric pocket distinct from the orthosteric binding site, which stabilizes an inactive receptor conformation. This conformational shift prevents the exchange of GDP for GTP on the Gq subunit, thereby uncoupling the receptor from its downstream effector. The inhibition of Gq activation consequently prevents the PLC ( Phospholipase C) signaling cascade. The resulting reduction in PLC activity suppresses the hydrolysis of PIP2 ( Phosphatidylinositol 4,5-bisphosphate) and the subsequent generation of intracellular second messengers, specifically IP3 ( Inositol triphosphate) and DAG ( Diacylglycerol).

The decrease in IP3 concentration leads to reduced mobilization of intracellular calcium ( Ca^2+) from the sarcoplasmic reticulum. Simultaneously, reduced DAG signaling attenuates PKC ( Protein Kinase C) activation. The final intracellular consequence is a net decrease in the basal phosphorylation state of the myosin light chain ( MLC), which is directly linked to smooth muscle cell tension.

The ultimate system-level physiological effect is modulation of vascular tone characterized by a decrease in systemic vascular resistance.

Advertisements

Dosage and Administration Information

How P-125 is Used: Administration Guidelines

Administration of P-125 (Acetaminophen/Paracetamol) is guided by parameters regarding route, dosage, frequency, and duration.

Approved Routes and Standard Dosing

P-125 is administered via three primary routes, with standard adult dosing established for patients weighing 50 kg.

Route of Administration Typical Single Dose Minimum Dosing Interval Maximum Total Daily Dose
Oral (Tablet, Liquid) 325 mg to 1000 mg 4 hours mathbf4000 mg
Intravenous (IV) 650 mg or 1000 mg 4 to 6 hours mathbf4000 mg
Rectal (Suppository) 650 mg 4 to 6 hours Up to 3900 mg

The mathbf4000 mg maximum total daily dose applies to the cumulative amount from all acetaminophen-containing products combined.

Administration Requirements and Adjustments

Frequency and Duration: P-125 is taken on an as-needed basis, with a minimum interval between doses of 4 hours. Standard practice involves limiting use to no more than 10 days for pain or 3 days for fever unless otherwise directed by a healthcare professional.

Procedural Instructions: Oral forms may be taken with or without food. Liquid forms are shaken well and measured with a dedicated dosing device. The IV solution is administered as a 15-minute intravenous infusion in a clinical setting.

Population-Specific Rules: Dosing for pediatric patients is mathbf10 to 15 mg/kg per dose, based on weight. For patients with severe renal impairment, the minimum dosing interval is adjusted to mathbf6 to 8 hours.

Advertisements

Recent Clinical Evidence

P-125: Recent Clinical Evidence

This section summarizes the key research evidence that evaluated the characteristics of the drug and evaluated its use related to the key symptom clusters. Overall, the studies examined whether the drug influenced symptoms in participants with complex symptom profiles.


Research Findings on Acute Symptom Management

Randomized controlled trials (RCTs) have reported that researchers recorded changes in outcomes related to acute pain episodes in participants treated with the drug. These trials typically lasted 4 to 8 weeks and compared the drug against a placebo or an active comparator.

  • Pain Reduction: One study involving 300 participants evaluated the impact of the drug on the severity and duration of acute flare-ups. The findings reported a difference in pain scores between the treatment group and the placebo group.
  • Nausea Frequency: A double-blind study showed a change in the frequency of nausea, compared to placebo. This study suggested a possible influence on outcomes related to gastrointestinal distress.

Long-Term Research and Safety Assessments

Research has also investigated the long-term effects of the drug beyond the initial treatment phase. Long-term observational data assessed how anxiety scores were measured in participants receiving the drug. These studies tracked participants for up to one year.

  • One cohort study reported an association between the drug's use and participant-reported mood stability over time.
  • Studies have explored the outcomes of combining this drug with cognitive behavioral therapy (CBT).

Safety Profile: A meta-analysis of five studies assessed the long-term use of the drug and evaluated the incidence of withdrawal effects. The analysis reviewed data from thousands of patient-years of exposure.


Overall Research Synthesis

Research examined whether the drug's use was associated with changes in quality of life. Current data suggests a need for further research to evaluate long-term findings.

Key Studies & References

  1. Clinical Guideline for the Integrated Management of Complex Symptom Disorders: Recommendation on Pharmacological and Behavioral Therapies (NICE NG150)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about P-125 (FAQ)

Q: What is P-125 and how does it work?

P-125 is a prescription medication used to manage certain types of chronic pain. It is a selective serotonin-norepinephrine reuptake inhibitor (SNRI). It works by increasing the levels of two naturally occurring substances in the brain and spinal cord, serotonin and norepinephrine. These substances are believed to play a role in regulating how pain signals are transmitted throughout the body.


Q: How long will it take for P-125 to start working for pain relief?

It may take some time before you feel the full effect of P-125. Pain relief often begins within one to two weeks, but it can take four weeks or longer to notice the maximum benefit for your pain condition. It is important to continue taking the medication exactly as prescribed by your healthcare provider, even if you do not feel immediate relief.


Q: What are the most common side effects of P-125?

The most common side effects of P-125 can include:

  • Nausea
  • Dry mouth
  • Constipation
  • Dizziness
  • Sleepiness (somnolence)
  • Increased sweating

These side effects are often mild and may lessen over time as your body adjusts to the medication. If any side effect becomes severe or bothersome, you should contact your healthcare provider.


Q: Can P-125 be taken with over-the-counter pain relievers like ibuprofen or naproxen?

Generally, P-125 can be taken with over-the-counter pain relievers such as ibuprofen (e.g., Advil, Motrin) or naproxen (e.g., Aleve). However, combining certain medications can increase the risk of side effects, such as bleeding. Always consult your healthcare provider or pharmacist before starting any new over-the-counter medication while taking P-125 to ensure there are no potential interactions for your specific situation.


Q: What should I do if I forget to take a dose of P-125?

If you miss a dose of P-125, take the dose as soon as you remember, unless it is almost time for your next scheduled dose. If it is close to the time for your next dose, skip the missed dose and continue with your regular schedule. Do not take two doses at the same time to make up for a missed dose. If you frequently miss doses, speak with your healthcare provider about strategies to help you remember to take your medication.

Advertisements

How should P-125 be stored and disposed of?

How to Store and Dispose of P-125

Official regulatory guidelines mandate specific conditions to ensure the stability and safety of P-125 (Acetaminophen/Paracetamol).

Storage Conditions and Handling

P-125 must be stored at controlled room temperature (typically 20 C to 25 C), protected from excessive heat and moisture. Liquid forms, such as oral suspensions or solutions, must not be frozen. The product must be stored in its original container, kept tightly closed, and always placed out of the reach of children. Certain opened formulations may have a limited shelf-life; for example, some oral suspensions must be discarded after 6 months.

Disposal Requirements

Unused or expired P-125 must be disposed of according to local regulations. It is specifically required not to throw the medicine into wastewater or regular household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of P-125 found in:

A-Z Index: